AstraZeneca says Calquence conditionally approved in China for first indication

AstraZeneca’s Calquence, a next generation, selective Bruton’s tyrosine kinase inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma, or MCL, who have received at least one prior therapy, the company announced. "This is the first approved indication for Calquence in China," AstraZeneca stated.